We show that PDI-1 is a potent competitive inhibitor of PD-1/PD-L1 binding and suppresses tumor growth in vivo through a mechanism involving inhibition of TCR/CD28-dependent signaling, enhancement of anti-tumor cytotoxicity, and increased inflammatory cytokine production. This evidence concerns the gene PDCD1 and neoplasm.